

INFORMATION DISCLOSURE CITATION IN AN **APPLICATION** (PTO-1449)

INFORMATION DISCLOSURE CITATION IN AN APPLICATION (PTO-1449)					ATTY. DOCKET NO. 114232.109			SERIAL NO. 09/518.076		
					APPLICANT Leland SI		PIRO	Leland SHAPIR SHEET 1 OF SERIAL NO. 09/518,076		
					FILING DATE March 3, 2000		GROUP 1614			
TYPE S	KLY		US PATE	NT DO	CUMENTS:	验			334.40	N. C.
(aminer': Iti <mark>all</mark> s	;	PATENT NO.	DATE		NAME		CLASS		BCLASS	FILING DATE
W	AA	4,657,763	4/14/87	Fink	elstein et al.	1	CLINOS	1	ocunss.	DATE
	AB	4,732,973	3/22/88	1	r et al	1		\sqcap		
	AC	4,839,283	6/13/89	Kaw	asaki et al					
	AD	5,166.134	11/24/92	Lezo	ley et al.					
	AE	5,476,995	12/19/95	Clar	k et al			Γ		
	AF	5,489,593	2/6/96	Paln	ner et al.					
	AG	5,504,095	4/2/96	Nak	ane et al.					
	AH	5,529,920	6/25/96	Cole	et al.		1		``	
	AI	5,565,334	10/15/96	Kufe	et al				1	
	AJ	5,567,682	10/22/96	Pert			1		1	
	AK	5,604,201	2/18/97	Thor	nas et al.		_/		1	
	AL	5,641,670	6/24/97	Trec	o et al				1	<u>.</u>
	AM	5,665,589	9/9/97	_	is et al	_	-	 -	+	
	AN	5,780,009	7/14/98		tzas et al		1		-\ 	
	AO	5,804,594	9/8/98	Mura		_	- \ 	<u> </u>	- \	
{ }	AP	5,817,484	10/6/98	Yu e						
V	AQ	5,914,342	6/22/99	-	rer et al.		1		- 1	
V										
,	 									
			·							

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



Leland SHAPIRO SHEET 2 OF 4

INFORMATION DISCLOSURE CITATION IN AN					ATTY. DOCKET NO. 114232.109 SERIAL NO. 09/518,076 APPLICANT Leland SHAPIRO FILING DATE GROUP May 3, 2000 GROUP DOCUMENTS OF TRANSLATION OUNTRY CLASS SUBCLASS			CACA	NOV	Š	5,		
APPLICATION (PTO-1449)					FILING D. May 3, 200	ATE	GROUP 1614		_\$	rs o	370	35	
新三规 题	27	新疆		FOREIGN PA	FENT	DOCUMENT	S.M. COLUMN				1 '	3	
EXAMINE INITIAL		·	PATENT NO.	DATE	С	OUNTRY	CLASS	SUBCLASS	Trans Yes	ation No		Q	,
M		BA	WO95/28422	10/26/95	PCT		\	1	T		İ		
		BB	WO95/34538	12/21/95	PCT	•							
		вс	WO96/12021	4/25/96	PCT								
		BD	WO96/14067	5/17/96	PCI	•							
		BE	WO97/31937	9/4/97	PCI	,							
		BF	WO00/52034					\	†				
		BG	WO99/43308	9/2/99	_	7	1				I		
v		вн	WO94/07525 ~	_	wo		1	1					
	_												
	\dashv			<u> </u>				 	_				
	+		·			· · · · · · · · ·							
								ļ					
	\dashv							 	 	-			
EXAMIN	ER		m - 1	nhX	D	ATE CONS	IDERED	04	<u> </u>				

EXAMINER: Initial if reference considered, whether or hot citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.





INFORMATION DISCLOSURE CITATION IN AN APPLICATION (PTO-1449)

ATTY. DOCKET NO. 114232.109

SERIAL NO. 09/518,076

APPLICANT

Leland SHAPIRO

FILING DATE May 3, 2000 GROUP 1614

		May 3, 2000							
		OTHER ART (Including/Author, Title, Date, Pertineut Pages, Etc.)							
my	CA	Altieri, D.C. J Leukoc Biol 1995, 58, 120127							
	СВ	Animal Cell Culture, R. I. Freshney, ed., 1986							
	cc	Auerswald et al., "Recombinant leech-derived tryptase inhibitor: construction, production, protein chemical characterization and inhibition of HIV-1 replication", Biol Chem Hoppe Seyler, 375(10):695-703 (1994)							
	CD	Beal, M.F., "Mitochondria, Free Radicals, and Neurodegeneration", Curr. Opin. Neurobiol., 1996, 6, 661-666							
	CE	Beck, K.F. et al. in <i>J Exp Biol 1999</i> , 202, 64553 Cilberto et al., 1995, <i>Cell</i> , 41:531-540							
	CF								
	CG	Deigner, H.P. and R. Kinscherf, "Modulating Apoptosis: Current Applications and Prospects for Future Drug Development", Curr Med Chem 1999, 6, 399-414							
	СН	Dery, O. and Bunnett, N.W. Biochem Soc Trans 1999, 27,246-254							
	CI	Dery, O. et al. Am J Physiol 1998, 2 74, C 1429-C 1452							
	a	Ding, A. et al., in J. Immunol. 1990, 145, 940							
·	СК	Goureau, 0. et al., in Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 4276							
	Gu M, Rappaport J, Leppla SH., "Furin is important but not essential for the maturation of gp160 of HIV-1", FEBS Lett, 22;365(1):95-7 (May 10, 1995)								
	СМ	Heck, D. E. et al., in J. Biol. Chem. 1990, 267, 21277							
	CN	Inocencio et al., "Endoprotease activities other than furin and PACE4 with a role in processing of HIV-I gp160 glycoproteins in CHO-KI cells", J Biol Chem, 272(2):1344-(1997)							
	со	Jabs, Thorsten, "Reactive Oxygen Intermediates as Mediators of Programmed Cell Deal in Plants and Animals", Biochem Pharmacol 1999 57, 231-245							
•	СР								
	cQ	Kidd, Vincent J., PROTEOLYTIC ACTIVITIES THAT MEDIATE APOPTOSIS, Annu Rev Physiol, 1998, 60, 533							
	CR	Kido H, Niwa Y, Beppu Y, Towatari T. Cellular proteases involved in the pathogenicity of enveloped animal viruses, human immunodeficiency virus, influenza virus A and Sendai virus. Adv Enzyme Regul 1996;36:325-47							
	cs	Kirkeboen, K.A. and Strand, O.A. in Acta Anaesthesiol Scand 1999, 43, 275							
	СТ	Langer, R. Nature 1998, 392, 5							
XAMINE	ER	DATE CONSIDERED							

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in onformance and not considered. Include copy of this form with next communication to Applicant.



Leland SHAPIRO SHEET 4 OF 4

INF		MATION DISCLOSURE	ATTY. DOCKET NO. 114232.109 APPLICANT	SERIAL NO. 09/518,076 CHO 101 GROUP 1614				
ļ		APPLICATION	Leland SHAPIRO					
		(PTO-1449)	FILING DATE May 3, 2000	GROUP ISIA				
		OTHER ART (Including Author, Tit		1				
W	cu	Best, P.J.M., et al., Arterioscler Thron						
	CV	Lomas DA, Elliott PR, Carrell RW. Commercial plasma alphal-antitrypsin (Prolastin) contains a conformationally inactive, latent component. Eur Respir J 1997 Mar;10(3):672-5						
	cw	Lowenstein, C. J. and Snyder, S.H. in	Cell 1992, 70, 705-707					
	сх	Lowenstein C. J. et al. in Proc. Natl.	Acad. Sci. USA, 1993, 90,	9730				
	CY	McCall, T.B. et al., in Biochem. Bioph	ys. Res. Commun. 1992,18	86, 680				
	cz	Meylan et al., "HIV infectivity is not at human mast-cell tryptase", AIDS, 6(1)	ugmented by treatment with: :128-30 (1992)	trypsin, Factor Xa or				
	CAA	Miranda et al., "Isolation of the human PC6 gene encoding the putative host protease for HIV-1 gp160 processing in CD4+ T lymphocytes", Proc Natl Acad Sci U S A, 93(15):7695-7700) (1996)						
	CAB	Molle W. et al. in <i>J Immunol</i> 1997, 159, 3555						
	CAC	Morel, J. B. and Dangle, J.L., Cell Death Differ 1997, 4, 67 1						
·	CAD	Nathan, C. in FASEB J. 1992, 6, 3051						
	CAE	Ohnishi et al., "A furin-defective cell line is able to process correctly the gp160 of human immunodeficiency virus type 1", J Virol, 68(6):4075-99 (1994)						
	CAF	Okumura et al., "The extracellular processing of HIV- I envelope glycoprotein gp160 by human plasmin", FEBS Lett, 442(1):39-42 (1998)						
	CAG	Patel R.P., et al. in Biochim Biophys Acta 1999, 1411,385-400						
	CAH Popko B. and Baerwald, K. D. in Neurochem Res 1999, 24, 33 1 (Abstract)							
	CAI	Premack, B. A. and Schall, T. J., "Chemokine Receptors: Gateways to Inflammation and Infection", Nature Medicine, 2, 1174-1178 (1996)						
	CAJ	Punjabi, C. J. et al., in J. Immunol. 199	2, 149, 2179					
•	CAK	Remington's Pharmaceutical Sciences 1990, pp. 1519-1675, Gennaro, A. R., ed., Mack Publishing Company, Easton, PA.						
	CAL	Sambrook, Fritsch & Maniatis, Molecular Cloning: A Laboratory Manual, Second Edition 1989, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.						
	CAM	Schini et al. in Circ Res 1994, 74, 24						
	CAN	Schwartz, et al., "Antiviral activity of the proteasome on incoming human immunodeficiency virus type I", J Virol, 72(5):3845-50) (1998)						
111	CAO	Smith, M. E. in Neurochem Res 1999,						
V	САР	Wood, E.R. et al. in Biochem Biophys I	Res Commun 1993,191, 767	7-74				
EXAMIN	EXAMINER DATE CONSIDERED							

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.